This live webinar will discuss the following topics:

• Are CMC and formulation efforts treated as the foster child in the innovation and development armament?
• Underestimating CMC and formulation aspects can potentially cause significant delays and project failures
• Appropriate (what, how and when) CMC and formulation innovation and development strategies can improve overall probability of project success, can bring competitive advantages (including IP umbrella) and can reduce time to market
• Do it right the first time!

Speaker: Aleksandar Danilovski, Chief Scientific Officer, Xellia Pharmaceuticals (Denmark)

Moderator: Michael Scholl, Chief Executive Officer, Leukocare AG (Germany)

The presentation will be followed by a Q&A session.